In acidosis, catecholamines are attenuated and higher doses are often required to 26 improve cardiovascular function. Colforsin activates adenylate cyclase in cardiomyocytes 27 without mediating the beta adrenoceptor. In this study, six beagles were administered 28 either colforsin or dobutamine four times during eucapnia (partial pressure of arterial 29 carbon dioxide 35-40 mm Hg; normal) and hypercapnia (ibid 90-110 mm Hg; acidosis) 30 conditions. The latter was induced by carbon dioxide inhalation. Anesthesia was induced 31 with propofol and maintained with isoflurane. Cardiovascular function was measured by 32 thermodilution and a Swan-Ganz catheter. Cardiac output, heart rate, and systemic 33 vascular resistance were determined at baseline and 60 min after 0.3 μg/kg/min (low), 0.6 34 μg/kg/min (middle), and 1.2 μg/kg/min (high) colforsin administration. The median pH 35 was 7.38 [range 7.34-7.42] and 7.04 [range 7.01-7.08] at baseline in the Normal and 36 Acidosis conditions, respectively. Endogenous adrenaline and noradrenaline levels at 37 baseline were significantly (P < 0.05) higher in the Acidosis than in the Normal condition. 38 Colforsin induced cardiovascular effects similar to those caused by dobutamine. 39 Colforsin increased cardiac output in the Normal condition (baseline: 198.8 mL/kg/min 40 [range 119.6-240.9], low: 210.8 mL/kg/min [range 171.9-362.6], middle: 313.8 41 mL/kg/min [range 231.2-473.2], high: 441.4 mL/kg/min [range 373.9-509.3]; P < 0.001) 42 and the Acidosis condition (baseline: 285.0 mL/kg/min [range 195.9-355.0], low: 297.4 43 mL/kg/min [213.3-340.6], middle: 336.3 mL/kg/min [291.3-414.5], high: 366.7 44 mL/kg/min [339.7-455.7] ml/kg/min; P < 0.001). Colforsin significantly increased heart
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in the Acidosis than in the Normal condition (P < 0.001). Dobutamine increased Introduction warming machine (Bair Hugger; 3M Japan Co. Ltd., Tokyo, Japan). 140 After the dogs were instrumented, the normal and acidotic conditions were 141 adjusted according to the arterial blood gas data. Arterial-and mixed venous blood gases 142 were measured by collecting 1.0 mL blood from the dorsal pedal-and pulmonary arteries 143 catheterized to a heparinized syringe. Blood gas measurements (GEM-Premier 3000; IL 144 Japan Co. Ltd., Tokyo, Japan) were corrected to body temperature. When the 145 cardiovascular parameters were being measured in the normal condition (Normal), the 146 arterial partial pressure of carbon dioxide (PaCO 2 ) was maintained at ~35-40 mm Hg. 147 When the cardiovascular parameters were being measured in the acidotic condition 148 (Acidosis), the PaCO 2 was maintained at ~90-110 mm Hg and the pH was ~7.0.
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Exogenous hypercapnia was induced by adding dry gaseous carbon dioxide (CO 2 ) to the 150 inspiratory corrugated tube of the anesthesia circuit. 
Evaluation of cardiovascular parameters
All dogs were stabilized for 30 min after preparation. Then, baseline 154 cardiovascular parameters and arterial-and mixed venous blood gases were measured and 155 recorded as follows: heart rate (HR; beats/min) by electrocardiogram with a lead II, and 156 MAP, PAP, RAP, and PAOP by a multi-parameter anesthetic monitoring system (RMC-157 4000 Cardio Master; Nihon Kohden Corporation, Tokyo, Japan). Cardiac index (CI; 158 mL/min/kg), stroke volume (SVI; mL/beat/kg), systemic vascular resistance (SVRI; 159 dynes·sec·cm -5 /kg), and pulmonary vascular resistance (PVRI; dynes·sec·cm -5 /kg) were 160 calculated by inserting values into previously published formulae [8] . 161 After the baseline measurements, the dogs were intravenously infused with 162 colforsin (Adehl; Nihonkayaku Co. Ltd., Tokyo, Japan) or dobutamine (Dobutrex; 163 Shionogi & Co. Ltd., Osaka, Japan) through a 22-gauge catheter inserted into the left 164 cephalic vein. Colforsin administration was gradually increased to 1 mL/h (0.3 165 μg/kg/min), 2 mL/h (0.6 μg/kg/min), and 4 mL/h (1.2 μg/kg/min) every 60 min. Similarly, 166 dobutamine administration was gradually increased to 1 mL/h (5 μg/kg/min), 2 mL/h (10 167 μg/kg/min), and 4 mL/h (20 μg/kg/min) every 60 min. Colforsin and dobutamine were 168 diluted with sterile saline (normal saline; Otsuka Pharmaceutical Factory Inc., Tokyo, 169 Japan) and administered by infusion pump (TOP-5500; TOP Co. Ltd., Tokyo, Japan). All 170 cardiopulmonary measurements were repeated every 60 min after each dose was 171 administered. When the cardiovascular parameters were determined after the final dose, 172 the arterial-and mixed venous blood gases were measured as described above. 173 After the experiment, all dogs received 0.2 mg/kg subcutaneous meloxicam 174 (Metacam; Boehringer Ingelheim Co. Ltd., Tokyo, Japan) and 0.01 mg/kg intramuscular 175 buprenorphine (Lepetan injection; Otsuka Pharmaceutical Factory Inc., Tokyo, Japan) for 176 analgesia and 25 mg/kg intravenous cefazolin (cefazolin sodium; Nichi-Iko Co. Ltd., Toyama, Japan) to prevent infection. For the Acidosis condition, carbon dioxide 178 inhalation was terminated and dog PaCO 2 was maintained at 35-40 mm Hg. They were 179 administered 0.5 g/kg intravenous mannitol (D-mannitol injection; Terumo Co. Ltd.,
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Tokyo, Japan) for 30 min to lower intracranial pressure. Colforsin and dobutamine were 181 washed out for 1 h and the dogs recovered from the anesthesia. Two milliliters of blood was drawn from the arterial catheter to measure baseline 185 catecholamine (adrenaline, noradrenaline, and dopamine) concentrations. The blood 186 samples were immediately centrifuged (1,000 × g for 10 min at 4° C) to separate the 187 plasma, which was then stored at -80 °C until analysis. Catecholamine levels were 188 determined by an external laboratory (BML Inc., Tokyo, Japan). In addition, 2 mL blood 189 was drawn from the arterial catheter at baseline and at the end of experiment, the plasma 190 was isolated from them as described above, and the samples were biochemically analyzed 191 (DRI-CHEM 7000V; Fujifilm Co. Ltd., Tokyo, Japan) in the laboratory at our facility. Blood gases and biochemical analyses in response to colforsin 206 The blood gas and biochemical test results at baseline and at the end of the 207 experiment are shown in Table 1 . The median pH at baseline was 7.38 (range 7.34-7.42) 208 for the Normal condition and 7.04 (7.01-7.08) for the Acidosis condition. In both cases, 209 the pH was slightly lower by the end of the experiment. The PaCO 2 at baseline was 39.5 210 mm Hg (range 34.0-41.1 mm Hg) for the Normal condition and 97.8 mm Hg (range 92.0-211 100.4 mm Hg) for the Acidosis condition.
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Blood adrenaline and noradrenaline levels were significantly higher in the 213 Acidosis than in the Normal condition at baseline (P < 0.05 for both). Plasma glucose 214 level was significantly (P < 0.05) higher in the Acidosis condition than the Normal 215 condition. In the former, plasma potassium was significantly (P < 0.05) higher at the end 216 of the experiment than it was at baseline. Although the peak plasma potassium was 8.3 217 mmol/L, no arrhythmia was observed.
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Cardiovascular effects of colforsin 220 The effects of colforsin on the cardiovascular parameters in the Normal and 221 Acidosis conditions are shown in Table 2 . There was an interaction between the effects 222 of colforsin and pH on both CI and SVRI. Baseline CI, HR, SVI, PAP, and PAOP were 223 higher and SVRI was lower in the Acidosis condition than the Normal condition, and the 224 differences were significant (P < 0.05). Relative to the baseline value, the rate of increase in CI in the Acidosis condition was greater than that in the Normal condition (Normal vs.
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Acidosis: 6% vs. 4%, 0.3 μg/kg/min; 58% vs. 18%, 0.6 μg/kg/min; 122% vs. 29%, 1.2 227 μg/kg/min). The SVI, DAP, RAP, SVRI, and PAOP were significantly (P < 0.05) 228 different between the Normal and Acidosis conditions. The blood gas and biochemical test results at baseline and at the end of the 246 experiment are shown in Table 3 . The pH at baseline was 7.38 (range 7.33-7.41) in the 247 Normal condition and 6.99 (range 6.96-7.05) in the Acidosis condition. In both cases, the 
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Blood adrenaline and noradrenaline levels were significantly higher in the 254 Acidosis condition than the Normal condition at baseline (P < 0.05). Plasma glucose was 255 significantly (P < 0.05) higher in the Acidosis condition than the Normal condition. In 256 the latter case, plasma potassium at the end of the experiment was significantly (P < 0.05) 257 higher than it was at baseline. Table 4 . There were no interactions between 262 dobutamine treatment and pH in terms of their effects on the cardiovascular parameters.
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The CI, SVI, PAP, and PAOP were higher and the SVRI was lower in the Acidosis 264 condition than the Normal condition at baseline, and the differences were significant (P 265 < 0.05). Relative to the baseline value, the rate of increase in CI in the Acidosis condition 266 was greater than that in the Normal condition (Normal vs. Acidosis: 46% vs. 44%, 5 267 μg/kg/min; 129% vs. 66%, 10 μg/kg/min; 157% vs. 82%, 20 μg/kg/min). The CI, HR, 
Table 1. The effects of colforsin on blood gas examination and blood biochemical test in six anesthetized dogs in eucapnia (Normal) and acute respiratory acidosis (Acidosis) at baseline and at the end of the experiment.

Variable (Unit)
Condition Baseline End of experiment .0] CI, cardiac index; HR, heart rate; SVI, stroke volume index; SAP, systolic arterial pressure; MAP, mean arterial pressure, DAP, diastolic arterial pressure; RAP, right atrial pressure; SVRI, systemic vascular resistance index; PAP, pulmonary arterial pressure; PAOP, pulmonary arterial occlusion pressure; PVRI, pulmonary vascular resistance index. The rank transformation version of two-way ANOVA applies on condition and dobutamine treatment. Superscript A, B, and C show significant difference (P < 0.05) from baseline, 5 μg/kg / min, and 10 μg/kg / min by Steel-Dwass, respectively. * shows a significant difference (P < 0.05) as compared with each dose in Normal condition.
Discussion
291
To the best of our knowledge, this study is the first to evaluate the dose-dependent 292 cardiovascular function of colforsin in dogs. Colforsin had a cardiovascular action similar to 293 that of dobutamine. It increased CI and HR and decreased SVRI in a dose-dependent manner.
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However, under acute respiratory acidosis, the rates of change in CI, HR, and SVRI were 295 attenuated with both colforsin and dobutamine. Therefore, colforsin and dobutamine doses may 296 have to be increased under respiratory acidosis. [7] . It was also reported that the cAMP level in cardiac muscle cells was higher in response to 357 colforsin than to catecholamines [7] . However, the cardiovascular effects of colforsin on CI, 358 HR, and SVRI resembled those of dobutamine in the present study. The rates of change in these 359 variables in response to both drugs were weaker under the Acidosis condition than under the 360 Normal condition. As cardiomyocyte cAMP was not measured here, it could not be determined 361 whether the same reaction was occurring as that reported in the previous study. Moreover, 362 acidic perfusate rather than hypercapnia was considered in that study. Hypercapnia is anesthetic and suppresses cardiovascular function [27, 28] . Consequently, even if the same isoflurane dose 364 was administered to both groups, anesthesia may have been more profound in the Acidosis 365 group than in the Normal group because the former presented with hypercapnia. For this reason, 366 the effects of colforsin and dobutamine may have been attenuated by hypercapnia. the present study, the PAP was higher in the Acidosis condition than in the Normal condition.
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In the experimental induction of microembolic pulmonary hypertension, high dobutamine doses 372 decreased pulmonary artery pressure [30] . In the present study, all dogs administered with 373 dobutamine showed pulmonary hypertension > 20 mm Hg. Although certain dogs presented 374 with pulmonary hypertension at high colforsin doses, their PAP was low relative to that induced 375 by dobutamine. Even under acidosis, the influence of colforsin on pulmonary artery pressure 376 was small compared with that of dobutamine. Therefore, the fact that colforsin had zero impact 377 on pulmonary artery pressure may facilitate its application as an adjunct to (or replacement for) also be warranted in veterinary patients. We set our acute respiratory acidosis model higher 387 than that required for lung-protective ventilation in order to differentiate the drug effects clearly. 389 and pulmonary blood vessel organization. In the present study, colforsin did not raise 390 pulmonary artery pressure in the Acidosis condition. It was reported that colforsin attenuates 391 bronchoconstriction-and pulmonary hypertension-induced serotonin infusion in dogs [35] . unknown. Nevertheless, the colforsin dose administered in the present study had no effect on 406 the plasma glucose level. Therefore, colforsin might be appropriate for diabetic patients whose 407 cardiovascular function must be improved without raising their plasma glucose levels. In the 408 future, the influence of colforsin administration on plasma insulin concentration should be 409 investigated.
ARDS often causes pulmonary hypertension as a result of hypoxic pulmonary vasoconstriction
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In the Acidosis condition, the baseline plasma potassium level was higher than that at 411 the end of the experiment. Lactic acidosis is probably not associated with major intracellular 412 shifts in potassium level. However, respiratory acidosis may influence the serum potassium concentration [39] . In the Normal condition, neither dobutamine nor colforsin increased plasma 414 potassium levels. Moreover, there was no significant difference in plasma potassium between 415 the Normal and Acidosis conditions at baseline. Relative to the baseline, however, plasma 416 potassium level was significantly higher in the Acidosis condition at the end of experiment.
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Plasma potassium level rose in 3.5 h (0.5 h for stabilization and 3 h for the experiment) after 418 the induction of acute respiratory acidosis. One acidotic dog receiving dobutamine (potassium 419 level = 7.5 mmol/L) showed atrial stasis at the end of the experiment. Since the sample size was 420 small in this assay, we could not confirm the relationship between dobutamine and arrhythmia. 
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We conducted this study assuming that pulmonary edema or ARDS may complicate 445 respiratory acidosis. However, there were certain limitations here. Although oxygenation is 446 impaired in pulmonary edema and ARDS, we did not conduct this experiment under hypoxemia 447 which stimulates the sympathetic nervous system and enhances cardiovascular function. We 448 wanted to clarify the cardiovascular effects of colforsin in normal dogs. Therefore, we 449 conducted this experiment with 100% oxygen carrier gas. Next, we used healthy dogs free of 450 heart or lung disease. Dogs with severe mitral valve insufficiency causing pulmonary edema or 451 ARDS already have depressed cardiorespiratory function. Therefore, administering colforsin 452 and dobutamine to these patients may produce different cardiovascular effects. Further studies 453 are needed to establish the effects of colforsin and dobutamine on these disease models and 454 clinical cases and to verify the safety and efficacy of colforsin. In turn, these findings could be 455 adapted to human medicine. 
